With this setting, GSEA disclosed that, in comparison with the sole blockade of either RSK2 or AKT, the combination of blockade in the two kinases proved more powerful effects on several critical gene sets involved in myeloma pathophysiologies, such as those associated with MYC, mTOR, STK33, ribosomal biogenesis, or cell-extrinsic stimuli of soluble factors. Here, RPS6KA3 is linked to plasma cell myeloma.